Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0799
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2637
    +0.0015 (+0.12%)
     
  • USD/JPY

    151.1900
    -0.1820 (-0.12%)
     
  • Bitcoin USD

    70,446.29
    -901.07 (-1.26%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Stryker Acquires Stanmore Implants For £35.6 million

Stryker Corporation (NYSE: SYK) acquired Stanmore Implants Worldwide Limited for £35.6 million from SIW Holdings Limited in an all cash transaction. According to the company, Stanmore Implants was an innovative orthopaedic business focused on serving the needs of surgeons that treat adult and juvenile orthopaedic oncology.

Stryker said Stanmore Implants' portfolio included both patient specific, as well as off-the-shelf implant systems aimed at limb salvage.

The company's President for Orthopaedics, David Flyod, said "The acquisition of Stanmore Implants provides Stryker with differentiated technologies designed to provide the most effective solutions for orthopaedic oncology surgeons. This addition underscores Stryker's commitment to our core joint replacement business and expands our presence in the global orthopaedic oncology market."

Similarly, Stanmore Implants CEO, Michael Mainelli, reacted by stating "The combination of Stryker's commitment to orthopaedic oncology and Stanmore's novel orthopaedic oncology solutions provides a unique opportunity to impact a broader group of patients globally."

Shares of the company traded 0.41 percent lower on Thursday.

See more from Benzinga

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement